Document Detail

Exenatide for once-weekly administration.
MedLine Citation:
PMID:  22789767     Owner:  NLM     Status:  MEDLINE    
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration. Here we discuss the place of Bydureon in the management of type 2 diabetes mellitus.
Related Documents :
11206417 - Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
22437217 - Managing diabetes with integrated teams: maximizing your efforts with limited time.
3053747 - Advantageous metabolic effects of pulsatile insulin delivery in noninsulin-dependent di...
22787177 - A randomized, controlled study of once-daily ly2605541, a novel long-acting basal insul...
8053757 - Catamenial insulin reactions treated with a long-acting gonadotropin releasing hormone ...
18334777 - Role of plasma viscosity and plasma homocysteine level on hyperinsulinemic obese female...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Drug and therapeutics bulletin     Volume:  50     ISSN:  1755-5248     ISO Abbreviation:  Drug Ther Bull     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-13     Completed Date:  2012-10-09     Revised Date:  2013-05-13    
Medline Journal Info:
Nlm Unique ID:  0112037     Medline TA:  Drug Ther Bull     Country:  England    
Other Details:
Languages:  eng     Pagination:  78-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Delayed-Action Preparations
Diabetes Mellitus, Type 2 / drug therapy*
Drug Administration Schedule
Drug Costs
Glucagon-Like Peptide 1 / administration & dosage,  analogs & derivatives
Hypoglycemic Agents / administration & dosage*,  adverse effects,  economics
Injections, Subcutaneous
Insulin / administration & dosage
Middle Aged
Peptides / administration & dosage*,  adverse effects,  economics
Treatment Outcome
Venoms / administration & dosage*,  adverse effects,  economics
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Hypoglycemic Agents; 0/Insulin; 0/Peptides; 0/Venoms; 141732-76-5/exenatide; 839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With C...
Next Document:  An introduction to the methods of cost-effectiveness analysis.